SBI Securities Co. Ltd. Makes New $277,000 Investment in Cerus Co. (NASDAQ:CERS)

SBI Securities Co. Ltd. acquired a new stake in shares of Cerus Co. (NASDAQ:CERS - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 180,190 shares of the biotechnology company's stock, valued at approximately $277,000. SBI Securities Co. Ltd. owned approximately 0.10% of Cerus as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of CERS. Creative Planning increased its holdings in shares of Cerus by 51.3% during the third quarter. Creative Planning now owns 24,809 shares of the biotechnology company's stock valued at $43,000 after acquiring an additional 8,411 shares in the last quarter. Easterly Investment Partners LLC increased its holdings in shares of Cerus by 726.1% during the third quarter. Easterly Investment Partners LLC now owns 313,522 shares of the biotechnology company's stock valued at $546,000 after acquiring an additional 275,569 shares in the last quarter. Los Angeles Capital Management LLC grew its holdings in Cerus by 153.7% during the third quarter. Los Angeles Capital Management LLC now owns 195,224 shares of the biotechnology company's stock worth $340,000 after buying an additional 118,280 shares in the last quarter. Bouvel Investment Partners LLC grew its holdings in Cerus by 87.1% during the third quarter. Bouvel Investment Partners LLC now owns 505,020 shares of the biotechnology company's stock worth $879,000 after buying an additional 235,082 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in Cerus during the third quarter worth $353,000. Institutional investors own 78.37% of the company's stock.

Remove Ads

Insider Buying and Selling at Cerus

In other Cerus news, CEO William Mariner Greenman sold 23,023 shares of the company's stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $1.55, for a total value of $35,685.65. Following the completion of the transaction, the chief executive officer now owns 3,230,000 shares in the company, valued at $5,006,500. This represents a 0.71 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Kevin Dennis Green sold 60,656 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $1.58, for a total value of $95,836.48. Following the completion of the transaction, the chief financial officer now owns 493,862 shares of the company's stock, valued at $780,301.96. This trade represents a 10.94 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 165,713 shares of company stock worth $264,812 in the last quarter. 3.40% of the stock is currently owned by company insiders.

Cerus Stock Down 1.3 %

Cerus stock traded down $0.02 during trading on Friday, hitting $1.51. 1,867,261 shares of the company were exchanged, compared to its average volume of 1,505,992. The business's 50 day moving average is $1.74 and its 200 day moving average is $1.79. Cerus Co. has a 52 week low of $1.38 and a 52 week high of $2.54. The company has a market capitalization of $280.54 million, a P/E ratio of -13.73 and a beta of 1.56. The company has a current ratio of 2.59, a quick ratio of 1.92 and a debt-to-equity ratio of 1.19.

Cerus (NASDAQ:CERS - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.01). The firm had revenue of $50.81 million during the quarter, compared to the consensus estimate of $50.81 million. Cerus had a negative return on equity of 40.55% and a negative net margin of 11.60%. Analysts predict that Cerus Co. will post -0.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reiterated an "overweight" rating and set a $4.00 price target on shares of Cerus in a report on Friday, February 21st.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.